Buchert and colleagues124 reported on 83 patients (median age 54 years) with FLT3-ITD AML post allogeneic SCT who were randomized to sorafenib 200–400 mg twice daily for two years versus placebo. The gene discussed is FLT3; the disease is acute myeloid leukemia.